Cite
Rivaroxaban vs. warfarin on extended deep venous thromboembolism treatment: A cost analysis.
MLA
Diken, Adem İ., et al. “Rivaroxaban vs. Warfarin on Extended Deep Venous Thromboembolism Treatment: A Cost Analysis.” Phlebology, vol. 33, no. 1, Feb. 2018, pp. 53–59. EBSCOhost, https://doi.org/10.1177/0268355516688358.
APA
Diken, A. İ., Yalçınkaya, A., Hanedan, M. O., Erol, M. E., & Ercen Diken, Ö. (2018). Rivaroxaban vs. warfarin on extended deep venous thromboembolism treatment: A cost analysis. Phlebology, 33(1), 53–59. https://doi.org/10.1177/0268355516688358
Chicago
Diken, Adem İ, Adnan Yalçınkaya, Muhammet O. Hanedan, Mehmet E. Erol, and Özlem Ercen Diken. 2018. “Rivaroxaban vs. Warfarin on Extended Deep Venous Thromboembolism Treatment: A Cost Analysis.” Phlebology 33 (1): 53–59. doi:10.1177/0268355516688358.